Women with bipolar disorder often experience fluctuating mood symptoms across the menstrual cycle, typically reporting an exacerbation of symptoms during the premenstrual phase of the cycle (Rasgon et al, 2003, 2005). Â Other studies have indicated [...]
Aromatase inhibitors (AIs) are the preferred hormonal therapy for postmenopausal women with estrogen sensitive breast cancer. While the selective estrogen receptor modulators (SERMs), such as tamoxifen and raloxifene, are used in premenopausal women with estrogen sensitive breast cancer, the aromatase inhibitors (e.g., anastrozole, letrozole, and exemestane) have been shown to be more effective and safer than the SERMs in postmenopausal women.Â
